文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

StratosPHere 2:评估羟氯喹和苯丁酸盐治疗BMPR2突变所致肺动脉高压的应答适应性随机安慰剂对照II期试验研究方案

StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2.
PubMed 文献 · Trials · 2024-10-15

该方案描述一项三臂II期精准医学研究,按BMPR2错义突变和单倍剂量不足突变分层,采用贝叶斯应答适应性随机设计,在标准治疗基础上比较羟氯喹、苯丁酸盐与安慰剂,评估BMPR2靶点结合及疗效,探索不同突变类型的差异反应。

要点

  • 首个直接靶向挽救BMPR2通路的试验,老药新用羟氯喹和苯丁酸盐。
  • 按BMPR2错义突变和单倍剂量不足突变分层,各层独立进行贝叶斯应答适应性随机。
  • 三臂分别为两个活性治疗臂和安慰剂臂,均加标准治疗。

核心结论

  • 该试验将提供这些疗法挽救BMPR2功能的首次随机证据,并高效探索不同突变类型间的差异反应潜力。

研究设计与样本

  • 三臂II期精准医学研究,纳入BMPR2突变的肺动脉高压患者,按错义突变和单倍剂量不足突变两类分层。
  • 符合条件受试者随机分配至两个活性治疗臂或安慰剂臂,均加标准治疗,在各层内独立实施贝叶斯应答适应性设计。

主要发现

  • 研究将评估BMPR2靶点结合,并探索两种老药新用疗法在BMPR2突变肺动脉高压患者中的疗效。
  • 采用一组新型主要生物标志物评估疾病的生物学修饰,并据此更新随机分配。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension is a life-threatening progressive disorder characterised by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery). Although treatable, there is no known cure for this rare disorder, and its exact cause is unknown. Mutations in the bone morphogenetic protein receptor type-2 (BMPR2) are the most common genetic cause of familial pulmonary arterial hypertension. This study represents the first-ever trial of treatments aimed at directly rescuing the BMPR2 pathway, repurposing two drugs that have shown promise at restoring levels of BMPR2 signalling: hydroxychloroquine and phenylbutyrate. METHODS: This three-armed phase II precision medicine study will investigate BMPR2 target engagement and explore the efficacy of two repurposed therapies in pulmonary arterial hypertension patients with BMPR2 mutations. Patients will be stratified based on two BMPR2 mutation classes: missense and haploinsufficient mutations. Eligible subjects will be randomised to one of the three arms (two active therapy arms and a placebo arm, all plus standard of care) following a Bayesian response-adaptive design implemented independently in each stratum and updated in response to a novel panel of primary biomarkers designed to assess biological modification of the disease. DISCUSSION: The results of this trial will provide the first randomised evidence of the efficacy of these therapies to rescue BMPR2 function and will efficiently explore the potential for a differential response of these therapies per mutation class to address causes rather than consequences of this rare disease. TRIAL REGISTRATION: The study has been registered with ISRCTN (ISRCTN10304915, 22/09/2023).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Deliu N, Das R, May A, et al. StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2. Trials. 2024. PMID: 39407331. doi:10.1186/s13063-024-08485-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。